{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:15:47Z","timestamp":1794694547261,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Grant No. 82370175"],"award-info":[{"award-number":["Grant No. 82370175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017668","name":"Key Research and development Project of Anhui Province","doi-asserted-by":"crossref","award":["Grant No. 201904a07020057"],"award-info":[{"award-number":["Grant No. 201904a07020057"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Foundation of Anhui Medical University","award":["Grant No.2020xkj166"],"award-info":[{"award-number":["Grant No.2020xkj166"]}]},{"name":"Clinical Trial Initiative Projects of The First Affiliated Hospital of Anhui Medical University","award":["Grant No. LCYJ2021YB009"],"award-info":[{"award-number":["Grant No. LCYJ2021YB009"]}]},{"name":"Research Foundation of Anhui Institute of Translational Medicine","award":["Grant No. 2021zhyx-C32"],"award-info":[{"award-number":["Grant No. 2021zhyx-C32"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03825-8","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T10:35:27Z","timestamp":1748514927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Venetoclax synergizes with Wnt\/\u03b2-catenin inhibitor C-82 in acute myeloid leukemia by increasing the degradation of Mcl-1 protein"],"prefix":"10.1186","volume":"25","author":[{"given":"Mengya","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"3825_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"4","key":"3825_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Gui\u00e8ze","year":"2019","unstructured":"Gui\u00e8ze R, Liu VM, Rosebrock D, Jourdain AA, Hern\u00e1ndez-S\u00e1nchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36(4):369\u201384.","journal-title":"Cancer Cell"},{"issue":"1","key":"3825_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"7","key":"3825_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New Engl J Med. 2020;383(7):617\u201329.","journal-title":"New Engl J Med"},{"issue":"9","key":"3825_CR5","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404\u20137.","journal-title":"Haematologica"},{"issue":"8","key":"3825_CR6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/leu.2014.44","volume":"28","author":"JM Bogenberger","year":"2014","unstructured":"Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi C, Mantei J, Ahmann G, Gonzales IM, Choudhary A, et al. BCL-2 family proteins as 5-azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28(8):1657\u201365.","journal-title":"Leukemia"},{"issue":"12","key":"3825_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrm3470","volume":"13","author":"C Niehrs","year":"2012","unstructured":"Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Bio. 2012;13(12):767\u201379.","journal-title":"Nat Rev Mol Cell Bio"},{"issue":"8","key":"3825_CR8","first-page":"e302","volume":"100","author":"R Thijssen","year":"2015","unstructured":"Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MHJ, Kater AP, Eldering E. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302\u20136.","journal-title":"Haematologica"},{"issue":"2","key":"3825_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ajh.21334","volume":"84","author":"CC Chen","year":"2009","unstructured":"Chen CC, Gau JP, You JY, Lee KD, Yu YB, Lu CH, Lin JT, Lan C, Lo WH, Liu JM, et al. Prognostic significance of \u03b2-catenin and topoisomerase II\u03b1 in de novo acute myeloid leukemia. Am J Hematol. 2009;84(2):87\u201392.","journal-title":"Am J Hematol"},{"issue":"7","key":"3825_CR10","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3324\/haematol.2018.202846","volume":"104","author":"RG Morgan","year":"2019","unstructured":"Morgan RG, Ridsdale J, Payne M, Heesom KJ, Wilson MC, Davidson A, Greenhough A, Davies S, Williams AC, Blair A, et al. LEF-1 drives aberrant \u03b2-catenin nuclear localization in myeloid leukemia cells. Haematologica. 2019;104(7):1365\u201377.","journal-title":"Haematologica"},{"issue":"6","key":"3825_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ccr.2010.10.032","volume":"18","author":"J Yeung","year":"2010","unstructured":"Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, So ACWE. \u03b2-catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 2010;18(6):606\u201318.","journal-title":"Cancer Cell"},{"issue":"2","key":"3825_CR12","first-page":"1387","volume":"41","author":"J Fu","year":"2019","unstructured":"Fu J, Si L, Zhuang Y, Zhang A, Sun N, Li D, Hao B, Ju X. Wnt\/\u03b2-catenin inhibition reverses multidrug resistance in pediatric acute lymphoblastic leukemia. Oncol Rep. 2019;41(2):1387\u201394.","journal-title":"Oncol Rep"},{"issue":"7570","key":"3825_CR13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong CY, Gilan O, Lam EYN, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525(7570):538\u201342.","journal-title":"Nature"},{"issue":"13","key":"3825_CR14","doi-asserted-by":"publisher","first-page":"10448","DOI":"10.3390\/ijms241310448","volume":"24","author":"R Kleszcz","year":"2023","unstructured":"Kleszcz R, Fr\u0105ckowiak M, Dorna D, Paluszczak J. Combinations of PRI-724 Wnt\/\u03b2-catenin pathway inhibitor with vismodegib, erlotinib, or HS-173 synergistically inhibit head and neck squamous cancer cells. Int J Mol Sci. 2023;24(13):10448.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3825_CR15","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1158\/1078-0432.CCR-17-1556","volume":"24","author":"X Jiang","year":"2018","unstructured":"Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, et al. Disruption of Wnt\/\u03b2-catenin exerts antileukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia. Clin Cancer Res. 2018;24(10):2417\u201329.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3825_CR16","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317.","journal-title":"Cancer Discov"},{"issue":"48","key":"3825_CR17","doi-asserted-by":"publisher","first-page":"eadh1436","DOI":"10.1126\/sciadv.adh1436","volume":"9","author":"Y Nishida","year":"2023","unstructured":"Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, et al. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023;9(48):eadh1436.","journal-title":"Sci Adv"},{"issue":"12","key":"3825_CR18","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal LJ, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566\u201381.","journal-title":"Cancer Discov"},{"key":"3825_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/OTT.S182443","volume":"12","author":"S Nassereddine","year":"2019","unstructured":"Nassereddine S, Lap CJ, Tabbara IA. Evaluating ivosidenib for the treatment of relapsed\/refractory AML: design, development, and place in therapy. Oncotargets Ther. 2019;12:303\u20138.","journal-title":"Oncotargets Ther"},{"key":"3825_CR20","doi-asserted-by":"publisher","first-page":"414179270","DOI":"10.1177\/2040620719882822","volume":"10","author":"G Richard-Carpentier","year":"2019","unstructured":"Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019;10:414179270.","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"3825_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Glytsou C, Zhou H, Narang S, Reyna DE, Lopez A, Sakellaropoulos T, Gong Y, Kloetgen A, Yap YS, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019;9(7):890\u2013909.","journal-title":"Cancer Discov"},{"issue":"7661","key":"3825_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99\u2013103.","journal-title":"Nature"},{"issue":"1","key":"3825_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41419-022-05528-8","volume":"14","author":"W Zhao","year":"2023","unstructured":"Zhao W, Zhang L, Zhang Y, Jiang Z, Lu H, Xie Y, Han W, Zhao W, He J, Shi Z, et al. The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest. Cell Death Dis. 2023;14(1):11.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3825_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1142\/S0192415X23500350","volume":"51","author":"X Li","year":"2023","unstructured":"Li X, Gao F, Wang X, Liu L, Gan Y, Han S, Zhou L, Li W, Li M. Curcumol exerts antitumor effect via inhibiting EGFR-Akt-Mcl-1 signaling. Am J Chin Med. 2023;51(3):741\u201360.","journal-title":"Am J Chin Med"},{"issue":"12","key":"3825_CR25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41419-022-05500-6","volume":"13","author":"M Li","year":"2022","unstructured":"Li M, Gao F, Li X, Gan Y, Han S, Yu X, Liu H, Li W. Stabilization of MCL-1 by E3 ligase TRAF4 confers radioresistance. Cell Death Dis. 2022;13(12):1053.","journal-title":"Cell Death Dis"},{"issue":"6","key":"3825_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","volume":"21","author":"U Maurer","year":"2006","unstructured":"Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006;21(6):749\u201360.","journal-title":"Mol Cell"},{"issue":"1","key":"3825_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/15384047.2020.1856756","volume":"22","author":"MJ Kim","year":"2021","unstructured":"Kim MJ, Chen G, Sica GL, Deng X. Epigenetic modulation of FBW7\/Mcl-1 pathway for lung cancer therapy. Cancer Biol Ther. 2021;22(1):55\u201365.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"3825_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41467-017-02693-9","volume":"9","author":"S Zhang","year":"2018","unstructured":"Zhang S, Zhang M, Jing Y, Yin X, Ma P, Zhang Z, Wang X, Di W, Zhuang G. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 2018;9(1):215.","journal-title":"Nat Commun"},{"issue":"1","key":"3825_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1172\/JCI92742","volume":"128","author":"G Chen","year":"2018","unstructured":"Chen G, Magis AT, Xu K, Park D, Yu DS, Owonikoko TK, Sica GL, Satola SW, Ramalingam SS, Curran WJ, et al. Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy. J Clin Invest. 2018;128(1):500\u201316.","journal-title":"J Clin Invest"},{"issue":"2","key":"3825_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27(2):405\u201319.","journal-title":"Cell Death Differ"},{"issue":"13","key":"3825_CR31","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1158\/0008-5472.CAN-16-3470","volume":"77","author":"M Ye","year":"2017","unstructured":"Ye M, Zhang Y, Zhang X, Zhang J, Jing P, Cao L, Li N, Li X, Yao L, Zhang J, et al. Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer. Cancer Res. 2017;77(13):3527\u201339.","journal-title":"Cancer Res"},{"issue":"1","key":"3825_CR32","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12967-023-04481-0","volume":"21","author":"F Ye","year":"2023","unstructured":"Ye F, Zhang W, Fan C, Dong J, Peng M, Deng W, Zhang H, Yang L. Antileukemic effect of venetoclax and hypomethylating agents via caspase-3\/GSDME-mediated pyroptosis. J Transl Med. 2023;21(1):606.","journal-title":"J Transl Med"},{"issue":"18","key":"3825_CR33","doi-asserted-by":"publisher","first-page":"8813","DOI":"10.7150\/thno.62521","volume":"11","author":"S Hsu","year":"2021","unstructured":"Hsu S, Li C, Lin I, Syue W, Chen Y, Cheng K, Teng Y, Lin Y, Yen C, Chiu C. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics. 2021;11(18):8813\u201335.","journal-title":"Theranostics"},{"issue":"6","key":"3825_CR34","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.immuni.2019.05.020","volume":"50","author":"N Van Opdenbosch","year":"2019","unstructured":"Van Opdenbosch N, Lamkanfi M. Caspases in cell death, inflammation, and disease. Immunity. 2019;50(6):1352\u201364.","journal-title":"Immunity"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03825-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T10:35:28Z","timestamp":1748514928000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03825-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3825"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03825-8","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University in China\u00a0(PJ 2024-09-47). The animal study was approved by the Animal Care Ethics Committee\u00a0(IACUC-20240301).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"According to the national legislation and the institutional requirements, written informed consent for participation was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}